How sponsors are rethinking data management operating models in an increasingly complex clinical landscape
As clinical development programmes become increasingly global and complex, sponsors continue to face pressure to deliver high‑quality data faster, more consistently and with greater operational efficiency. The approach taken to resource and oversee data management (DM) functions plays a critical role in determining delivery quality, scalability and long-term performance across studies and portfolios.
Increasingly, sponsors are reassessing traditional staffing approaches in favour of global Functional Service Provider (FSP) models that provide a more strategic, scalable, and cost-effective foundation for modern clinical development.
Moving beyond staffing to a true FSP partnership
Staffing models can be effective for short-term or ad hoc needs, allowing sponsors to quickly address immediate workload demands. However, as clinical portfolios grow and trial designs become more complex, this approach can create challenges related to consistency, accountability, and long-term value.
Managing multiple vendors, contractors, and fragmented resource pools often increases operational burden while limiting visibility across programmes. In contrast, modern FSP models shift the focus from individual resources to dedicated, sponsor-aligned teams that can provide greater continuity, accountability, and consistency across programmes.
For sponsors, the value of this approach often extends beyond resourcing, providing access to established governance structures, leadership oversight, and broader expertise that can support delivery consistency across studies. Data management teams increasingly require expertise across a broad range of applications, including electronic data capture (EDC) platforms, data review and visualisation tools, automation technologies and emerging AI-enabled capabilities. As these technology ecosystems continue to evolve, sponsors are seeking operating models that can provide access to specialised expertise while supporting the adoption of new tools and innovative ways of working.
Beyond access to talent, many organisations are evaluating operating models that offer the flexibility to respond to changing portfolio demands while maintaining consistency in delivery. Scalable team structures, established processes and long-term continuity can help support operational efficiency, preserve institutional knowledge and promote quality across studies and portfolios.
These approaches may also help address some of the challenges associated with traditional staffing models. Flexible resource deployment can support changing programme requirements, while established operating frameworks, governance structures and clearly defined accountability help organisations maintain visibility and oversight. As clinical development programmes become increasingly complex, many sponsors are prioritising delivery models that balance agility, compliance and long-term sustainability.
Cost-effective access to global talent and technology expertise
As competition for experienced data management professionals increases, sponsors are exploring ways to access global talent while maintaining consistent quality and oversight. In the FSP model, sponsors can leverage a combination of near‑shore, offshore, and follow‑the‑sun models to optimise cost efficiency without compromising quality or control. Compared with traditional staffing approaches, often characterised by premium rates, limited bench availability, and geographically constrained talent, a global FSP delivery model provides greater flexibility and predictability.
Access to experienced data management professionals remains a persistent challenge across the clinical development industry. As demand for specialised expertise grows and clinical programmes become increasingly global, sponsors are exploring operating models that provide access to broader talent pools while supporting consistency and scalability.
At the same time, data management teams are working within increasingly complex technology environments that include electronic data capture platforms, centralised monitoring solutions, data visualisation tools, automation technologies and emerging AI-enabled workflows. As these ecosystems continue to evolve, sponsors need delivery models that can provide access to specialised expertise and support the adoption of new technologies and ways of working.
Teams with experience across multiple therapeutic areas, platforms and programmes can help accelerate onboarding, facilitate knowledge transfer and bring valuable perspectives on best practices and process improvement. This breadth of experience can support more consistent delivery and help maintain momentum across studies and portfolios.
Talent retention is also becoming an increasingly important consideration when evaluating data management operating models. High attrition can disrupt delivery, increase training requirements and erode institutional knowledge. As a result, many sponsors are placing greater emphasis on continuity, knowledge retention and workforce stability as key contributors to long-term programme success.
Risk mitigation, leadership, and performance at scale
Risk mitigation is an important consideration within global FSP models. Programmes are often supported by experienced local leadership across all regions, underpinned by enabling functions such as HR, IT, and executive oversight. Local leadership can also provide essential cultural and market insight, helping organisations navigate regional employment practices, workforce dynamics and operational constraints without compromising delivery timelines.
FSP programmes can be supported through a variety of leadership models, depending on sponsor objectives, organisational structure and portfolio requirements. Examples include functional management, providing hands-on operational leadership and strategic oversight, or line management, focused on resource management, employee development, and administrative support. ICON frequently consults with sponsors on establishing the appropriate management model during programme implementation, helping ensure alignment with sponsor objectives while maintaining the flexibility to evolve as programme requirements and portfolio needs change.
Dedicated leadership with deep functional data management coupled with clear accountability structures is often a key characteristic of mature FSP models. Experienced leaders understand sponsor expectations, proactively manage delivery risks, and ensure alignment across teams and geographies. This structured approach may also help reduce some of the administrative burden often associated with managing dispersed resource models.
FSP performance is supported through clearly defined KPIs, transparent metrics, and governance frameworks. Greater visibility into performance and risk can enable organisations to take a more proactive approach to decision-making and continuous improvement across their portfolios, rather than reactive issue management. This performance‑driven partnership between sponsor and CRO supports reliable portfolio delivery and long‑term sponsor confidence.
Built for the realities of modern clinical development
In an environment where timelines, data quality, and regulatory compliance are non-negotiable, sponsors require more than short-term resourcing solutions. Increasingly, many are seeking a solution that provides a scalable, strategically aligned alternative, combining experienced teams, dedicated leadership, global reach, technology-enabled delivery, and clear accountability.
As clinical development becomes increasingly complex and data-driven, the value of FSP partnerships continues to grow. ICON partners with sponsors to embed dedicated teams that develop deep knowledge of sponsor processes, systems, and objectives, creating opportunities for continuous improvement, operational efficiencies, and the adoption of technology solutions that enhance study execution and portfolio performance.
For sponsors seeking consistency, flexibility, and long-term confidence in data management delivery, a global FSP data management model offers a compelling strategic advantage, bringing together specialised expertise, scalable global infrastructure, strong governance, and technology-enabled innovation to support the evolving demands of modern clinical development.
Connect with our experts
Learn how ICON’s clinical data science solutions can support your next study.
Author:
Greg Matts
In this section
-
Digital Disruption
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
- mHealth wearables
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
- Software as a medical device (SaMD)
-
Digital Disruption: Surveying the industry's evolving landscape
-
Patient Centricity
-
Accelerating clinical development through DHTs
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
- Representation and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Prioritising patient-centred research for regulatory approval
-
Accelerating clinical development through DHTs
-
Regulatory Intelligence
-
Accelerating access
-
Global regulatory strategies for immunology
-
Meeting requirements for Joint Clinical Assessments
-
Navigating the regulatory landscape in the US and Japan:
-
Preparing for ICH GCP E6(R3) implementation
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
Exploring FDA guidance for modern Data Monitoring Committees
-
Streamlining dossier preparation
-
Accelerating access
-
Therapeutics insights
-
Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
-
Central Nervous System
-
Bridging science and clinical operability for neurologic monoclonal antibodies
-
A mind for digital therapeutics
-
Challenges and opportunities in traumatic brain injury clinical trials
-
Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
-
ICON survey report: CNS therapeutic development
-
Bridging science and clinical operability for neurologic monoclonal antibodies
- Infectious Diseases
-
NASH
- Obesity
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Endocrine and Metabolic Disorders
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Demystifying the Systematic Literature Reviews
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
From bottlenecks to breakthroughs
-
Linguistic validation of Clinical Outcomes Assessments
-
More than monitoring
-
Optimising biotech funding
-
Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
-
Blended solutions insights
-
Clinical trials in Japan: An enterprise growth and management strategy
-
How investments in supply of CRAs is better than competing with the demand for CRAs
-
The evolution of FSP: not just for large pharma
-
Embracing a blended operating model
-
Observations in outsourcing: Survey results show a blended future
-
Clinical trials in Japan: An enterprise growth and management strategy
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
- Partnership insights
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Building a comparative evidence base using network meta-analysis
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
CMS Part D Price Negotiations: Is your drug on the list?
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Health technology assessment
-
Perspectives from US payers
-
Medical communications in early phase product development
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
The Role of ICER as an HTA Organisation
-
Integrating openness and precision for competitive advantage
-
Building a comparative evidence base using network meta-analysis
-
Blog
-
Videos
-
Webinar Channel